Ranbaxy Glucophage XR Generic Uses Barr's 180-Day Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr "selectively waived" its second-round of 180-day exclusivity to Ranbaxy. FDA had previously withdrawn tentative approval of Barr's ANDA due to concerns about the product's raw material supplier.